SG11202006431WA - Non-viral dna vectors and uses thereof for antibody and fusion protein production - Google Patents
Non-viral dna vectors and uses thereof for antibody and fusion protein productionInfo
- Publication number
- SG11202006431WA SG11202006431WA SG11202006431WA SG11202006431WA SG11202006431WA SG 11202006431W A SG11202006431W A SG 11202006431WA SG 11202006431W A SG11202006431W A SG 11202006431WA SG 11202006431W A SG11202006431W A SG 11202006431WA SG 11202006431W A SG11202006431W A SG 11202006431WA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- fusion protein
- protein production
- viral dna
- dna vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862630670P | 2018-02-14 | 2018-02-14 | |
US201862630676P | 2018-02-14 | 2018-02-14 | |
US201862680092P | 2018-06-04 | 2018-06-04 | |
US201862680087P | 2018-06-04 | 2018-06-04 | |
PCT/US2019/018016 WO2019161059A1 (en) | 2018-02-14 | 2019-02-14 | Non-viral dna vectors and uses thereof for antibody and fusion protein production |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006431WA true SG11202006431WA (en) | 2020-08-28 |
Family
ID=67619630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006431WA SG11202006431WA (en) | 2018-02-14 | 2019-02-14 | Non-viral dna vectors and uses thereof for antibody and fusion protein production |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220042035A1 (en) |
EP (1) | EP3752191A4 (en) |
JP (1) | JP2021513355A (en) |
KR (1) | KR20200120649A (en) |
CN (1) | CN111818942A (en) |
AU (1) | AU2019221642A1 (en) |
BR (1) | BR112020016288A2 (en) |
CA (1) | CA3091250A1 (en) |
IL (1) | IL276469A (en) |
MA (1) | MA51842A (en) |
MX (1) | MX2020008470A (en) |
PH (1) | PH12020551039A1 (en) |
SG (1) | SG11202006431WA (en) |
WO (1) | WO2019161059A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA51626A (en) * | 2018-01-19 | 2020-11-25 | Generation Bio Co | CLOSED END DNA VECTORS AVAILABLE FROM ACELLULAR SYNTHESIS AND PROCESS FOR OBTAINING DNA VECTORS |
US20220280427A1 (en) * | 2019-09-06 | 2022-09-08 | Generation Bio Co. | Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof |
WO2021169167A1 (en) * | 2020-02-29 | 2021-09-02 | Nanjing GenScript Biotech Co., Ltd. | Method for treating coronavirus infections |
DE102020111571A1 (en) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES |
CA3172591A1 (en) * | 2020-03-24 | 2021-09-30 | Douglas Anthony KERR | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
IL299925A (en) | 2020-07-27 | 2023-03-01 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
WO2022153957A1 (en) * | 2021-01-12 | 2022-07-21 | Jcrファーマ株式会社 | Nucleic acid molecule containing incorporated gene encoding fused protein of ligand and protein having physiological activity |
EP4284936A1 (en) * | 2021-01-26 | 2023-12-06 | Kriya Therapeutics, Inc. | Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same |
WO2023091708A1 (en) * | 2021-11-18 | 2023-05-25 | The Brigham And Women's Hospital, Inc. | Induced proteinopathy models |
WO2024125530A1 (en) * | 2022-12-12 | 2024-06-20 | 苏州荷光科汇生物科技有限公司 | Aav vector for infecting retina, adalimumab, and use thereof |
US11993783B1 (en) * | 2023-03-27 | 2024-05-28 | Genecraft Inc. | Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof |
CN116549632A (en) * | 2023-03-28 | 2023-08-08 | 中国人民解放军军事科学院军事医学研究院 | New application of anti-Lingo-1 antibody Opiciinumab and medicine for new application |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2256265T3 (en) * | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | DUVICATED PARVOVIRUS VECTORS. |
WO2003018771A2 (en) * | 2001-08-27 | 2003-03-06 | Genentech, Inc. | A system for antibody expression and assembly |
US8865881B2 (en) * | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
AU2015213770A1 (en) * | 2014-02-06 | 2016-09-01 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
US10577627B2 (en) * | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
CN115287301A (en) * | 2016-03-03 | 2022-11-04 | 马萨诸塞大学 | End-blocked linear duplex DNA for non-viral gene transfer |
WO2019032102A1 (en) * | 2017-08-09 | 2019-02-14 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Closed-ended, linear, duplex adenoassociated virus dna, and uses thereof |
EP3679148A4 (en) * | 2017-09-08 | 2021-06-09 | Generation Bio Co. | Lipid nanoparticle formulations of non-viral, capsid-free dna vectors |
KR20200051011A (en) * | 2017-09-08 | 2020-05-12 | 제너레이션 바이오 컴퍼니 | Modified closed-terminated DNA (CEDNA) |
KR20200067195A (en) * | 2017-10-18 | 2020-06-11 | 리젠엑스바이오 인크. | Antibody therapy after full-human translation |
MX2020005808A (en) * | 2017-12-06 | 2020-10-28 | Generation Bio Co | Gene editing using a modified closed-ended dna (cedna). |
MA51626A (en) * | 2018-01-19 | 2020-11-25 | Generation Bio Co | CLOSED END DNA VECTORS AVAILABLE FROM ACELLULAR SYNTHESIS AND PROCESS FOR OBTAINING DNA VECTORS |
MA52116A (en) * | 2018-03-02 | 2021-01-06 | Generation Bio Co | CLOSED END DNA VECTORS (CEDNA) FOR THE INSERTION OF TRANSGENS AT THE GENOMIC SAFE (GSH) LEVEL IN HUMAN AND WALL GENOMES |
-
2019
- 2019-02-14 CN CN201980013028.XA patent/CN111818942A/en active Pending
- 2019-02-14 US US16/968,990 patent/US20220042035A1/en active Pending
- 2019-02-14 EP EP19753655.0A patent/EP3752191A4/en active Pending
- 2019-02-14 SG SG11202006431WA patent/SG11202006431WA/en unknown
- 2019-02-14 KR KR1020207024274A patent/KR20200120649A/en unknown
- 2019-02-14 WO PCT/US2019/018016 patent/WO2019161059A1/en unknown
- 2019-02-14 BR BR112020016288-4A patent/BR112020016288A2/en unknown
- 2019-02-14 MX MX2020008470A patent/MX2020008470A/en unknown
- 2019-02-14 JP JP2020543344A patent/JP2021513355A/en active Pending
- 2019-02-14 AU AU2019221642A patent/AU2019221642A1/en active Pending
- 2019-02-14 MA MA051842A patent/MA51842A/en unknown
- 2019-02-14 CA CA3091250A patent/CA3091250A1/en active Pending
-
2020
- 2020-07-03 PH PH12020551039A patent/PH12020551039A1/en unknown
- 2020-08-03 IL IL276469A patent/IL276469A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL276469A (en) | 2020-09-30 |
KR20200120649A (en) | 2020-10-21 |
EP3752191A4 (en) | 2021-12-22 |
CA3091250A1 (en) | 2019-08-22 |
RU2020130010A (en) | 2022-03-14 |
US20220042035A1 (en) | 2022-02-10 |
AU2019221642A1 (en) | 2020-07-09 |
BR112020016288A2 (en) | 2020-12-15 |
MX2020008470A (en) | 2020-09-25 |
CN111818942A (en) | 2020-10-23 |
PH12020551039A1 (en) | 2021-08-23 |
JP2021513355A (en) | 2021-05-27 |
EP3752191A1 (en) | 2020-12-23 |
MA51842A (en) | 2020-12-23 |
WO2019161059A1 (en) | 2019-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276469A (en) | Non-viral dna vectors and uses thereof for antibody and fusion protein production | |
IL279510A (en) | Progranulin-fc polypeptide fusion proteins and uses thereof | |
HK1257518A1 (en) | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof | |
TWI799368B (en) | Anti-tl1a antigen binding proteins and related nucleic acids, expression vectors, host cells, pharmaceutical composition, methods and uses | |
IL254559A (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 | |
EP3454832A4 (en) | Gdf15 fusion proteins and uses thereof | |
IL279505A (en) | Chimeric transmembrane proteins and uses thereof | |
EP3287470A4 (en) | Novel recombinant bi-functional fusion protein and preparation and application therefor | |
EP3436576A4 (en) | Cell line for recombinant protein and/or viral vector production | |
EP3280727A4 (en) | Single-arm type i and type ii receptor fusion proteins and uses thereof | |
EP3880814A4 (en) | Fusion protein | |
EP3502143A4 (en) | Linker peptide for constructing fusion protein | |
ZA202100125B (en) | Novel fusion protein specific for cd137 and pd-l1 | |
EP3275895A4 (en) | Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof | |
IL275691A (en) | Single-domain antibody-cytosine deaminase fusion proteins | |
EP3757218A4 (en) | Fusion protein | |
IL278102A (en) | Fusion proteins containing cd47 antibodies and cytokines | |
EP3976642A4 (en) | Apoe antibodies, fusion proteins and uses thereof | |
EP3863657A4 (en) | Bi-functional fusion proteins and uses thereof | |
SG11202104912SA (en) | Fusion protein and use thereof | |
EP3426289A4 (en) | Antigen-binding fusion proteins with modified hsp70 domains | |
EP3668551A4 (en) | Apom-fc fusion proteins and uses thereof | |
SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
EP3849599A4 (en) | Pneumococcal fusion protein vaccines | |
ZA202102533B (en) | Fusion protein |